Download chapter (PDF 508kb)
Chapter at a glance
- Vaccines represent the best hope for large, rapid and affordable improvements in health in the developing world.
- Vaccines developed for affluent countries have already contributed greatly to improving the health of people in poor countries. A remarkable 75% of children receive a basic set of childhood immunizations. But because of shortcomings in financing and delivery, including delays in introduction of life-saving vaccines, more than 3 million people die each year of vaccine-preventable diseases.
- Increasingly, the main diseases in poor countries are not a high priority in affluent countries. As a result, developing countries can no longer depend on rich markets to meet the costs of the development of new vaccines that would benefit poor countries.
- The total market size for vaccines in developing countries is tiny? about $500 million a year. This is insufficient to provide an incentive for pharmaceutical companies to invest in developing new vaccines for these diseases.
- In addition to being small, the vaccine market is characterized by collective procurement. Success in stretching health budgets by keeping prices as low as possible has important short-term benefits. But the aim of minimizing shortterm costs to ensure access must be balanced with the goal of providing returns sufficient to stimulate development of new products.
- Largely as a result of the low value and high risks of the developing country market, less than 10% of global spending on health research and development is devoted to the major health problems of 90% of the population.
- Without a valuable market to stimulate the development of new vaccines for diseases that occur mainly in developing countries, alternative arrangements are needed to ensure that vaccines are developed, produced on a large scale and made available affordably and reliably to developing countries.
Read full chapter (PDF 508kb)